Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.62 |
| ▸ | AGXT | P21549 | 2/20 | 0.62 |
| ▸ | MAOB | P27338 | 7/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768643 | 0.88 | IDO1 (0.71) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL2091873 | 0.87 | IDO1 (0.61) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL12093572 | 0.83 | IDO1 (0.65) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL3160821 | 0.82 | TP53 (0.49) | IDO1AGXTMAOBCHRM2CHRM1 | |
| SCHEMBL6205292 | 0.81 | IDO1 (0.62) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL28382952 | 0.81 | IDO1 (0.68) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL11021612 | 0.81 | IDO1 (0.62) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL6205291 | 0.81 | IDO1 (0.62) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL1144902 | 0.81 | IDO1 (0.67) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL5315445 | 0.81 | TAAR1 (0.67) | IDO1AGXTMAOBTAAR1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CHEMRX ADVANCED TECHNOLOGIES, INC. | 2002-08-01 | — | — | US | claimed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| EP-2061789-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008032858-A2 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-20 | — | — | WO | disclosed |
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CHEMRX ADVANCED TECHNOLOGIES, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001040193-A1 | METHOD FOR THE SYNTHESIS OF PYRAZOLINES | CHEMRX ADVANCED TECHNOLOGIES, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103381-A1 | Method for the synthesis of pyrazolines | CYP2F1, CYP2E1, CYP3A7 | IDO1 859/4885AGXT 1400/4885MAOB 249/4885 |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | IDO1 1716/4885AGXT 3155/4885MAOB 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.